Clinical Effects of TRH Analog (DN-1417) on Lennox Syndrome
スポンサーリンク
概要
- 論文の詳細を見る
DN-1417 (γ-butyrolactone-γ-carbonyl-L-histidyl-L-prolinamide citrate), a TRH analog, was found to have potent central actions and only nominal endocrine activity.<BR>We have reported previously that DN-1417 markedly inhibited activation of paroxysmal discharges with photic stimulation, and improved myoclonus, cerebellar symptoms, psychic activity in one case of degenerative myoclonus epilepsy.<BR>In this paper, we report the clinical effects of DN-1417 on three cases of the Lennox syndrome. In addition to the preceding therapy with conventional anticonvulsants, the patients were injected i. m. with 0.5-1.0mg of DN-1417 everyday for two weeks.<BR>The drug was found to exert an excellent improvement in bradyphrenia and dysphoria. The drug also proved to have antiepileptic effects. The drug inhibited diffuse slow spike and wave complexes and improved dysrhythmia in the EEG. The effects of DN-1417 appeared either on clinical symptoms or the EEG within a week of treatment and persisted for 30 to 70 days after its withdrawal. Neither side effect nor abnormal laboratory findings were observed.
- 一般社団法人 日本てんかん学会の論文
一般社団法人 日本てんかん学会 | 論文
- Single Photon Emission computed Tomography (SPECT) with N-Isopropyl-p-(123I) iodoamphetamine in Children with Localization-related Epilepsies. A Comparison of the Early and Delayed Images.:A Comparison of the Early and Delayed Images
- Gliomas as Epileptogenic Lesions Investigated by CT scan
- A Case of Epilepsia Partialis Continua Accompanied by Series of Partial Seizures.
- A Clinical Study of Seventy Adult Patients with the Lennox-Gastaut Syndrome
- Induced Microseizures-A CIinical and Electroencephalographic Study